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Introduction {#sec001}
============

Transplantation of marginal organs from donors after circulatory arrest is an important option to reduce the waiting period for recipients. Progress has been made in perfusion of donor organs with diluted donor blood \[[@pone.0222863.ref001]\], but there are few methods that can be easily used at many sites where donors may be found.

Hydrogen gas has been shown to have various biological effects, including suppression of ischemia-reperfusion injury in animal studies \[[@pone.0222863.ref002]--[@pone.0222863.ref005]\]. Ischemia-reperfusion injury is an inevitable complication of solid organ transplantation and limiting this type of injury can increase graft survival. Use of hydrogen gas has been reported to be effective in transplantation models of various organs, including the small intestine \[[@pone.0222863.ref006]--[@pone.0222863.ref007]\], lung \[[@pone.0222863.ref008]--[@pone.0222863.ref014]\], liver \[[@pone.0222863.ref015]--[@pone.0222863.ref018]\], heart \[[@pone.0222863.ref019], [@pone.0222863.ref020]\], osteochondral tissue \[[@pone.0222863.ref021]\], and kidney \[[@pone.0222863.ref022]\]. It is possible to expose the excised organ to hydrogen gas ex vivo without the donor and/or recipient inhaling the gas, and various methods have been devised to dissolve hydrogen gas in organ preservation solutions, including use of a hydrogen gas cylinder \[[@pone.0222863.ref006]\], electrolysis \[[@pone.0222863.ref018], [@pone.0222863.ref020], [@pone.0222863.ref021], [@pone.0222863.ref022]\], or a hydrogen-generating agent \[[@pone.0222863.ref017]\]. However, these methods require bulky equipment and dangerous high-pressure cylinders with strict regulations for handling, resulting in the need to expend considerable time and effort for preparation. Therefore, it is probably unrealistic to attempt the introduction of such methods into the clinical setting. Accordingly, a simple technique for rapidly dissolving hydrogen gas in organ preservation solutions is required.

A hydrogen-absorbing alloy is a compound that absorbs hydrogen when it is cooled or pressurized and then releases hydrogen when it is heated or depressurized. A hydrogen-absorbing alloy canister is filled with such an alloy, and these canisters have been used to supply hydrogen for fuel cells. We have developed a method of using a hydrogen-absorbing alloy canister to rapidly and conveniently dissolve hydrogen in organ preservation solutions at high concentrations. The canister storing hydrogen can be safely transported anywhere and can be easily connected to a bag containing conventional organ preservation solution, allowing hydrogen to be dissolved in organ preservation solution within a few minutes at the site of donor organ harvesting.

In the present study, the efficacy and safety of cold organ preservation solution containing hydrogen dissolved by this method were tested in a miniature pig model of kidney transplantation from donors with circulatory arrest. Previous studies were performed in juvenile domestic pigs, but we used miniature pigs to more closely reflect the clinical setting \[[@pone.0222863.ref023]\]. After circulatory arrest for 30 minutes, kidneys were harvested from the donor, flushed out, and stored in either hydrogen gas-containing organ preservation solution or conventional organ preservation solution. Then early kidney function after transplantation was compared between the two methods of preservation.

Materials and methods {#sec002}
=====================

Miniature pigs {#sec003}
--------------

Conventionally, animal studies on kidney transplantation have been performed using juvenile domestic pigs (about 4 months old). However, the donors and recipients were adult miniature pigs in the present study because this was considered to more closely correspond to the clinical setting. Miniature pigs do not exceed 30 Kg in weight when fully grown after 2 years. We used female pigs aged 25--40 months and weighing 20--26 Kg, purchased from Fujimicra Ltd., Shizuoka, Japan. Animals were treated in accordance with the Animal (Scientific Procedures) Protection Act 1986 of the United Kingdom. The pigs were housed in cages under temperature and light-controlled conditions (12-hour light/dark cycle) and were provided with food and water ad libitum. The pigs were fasted for 12 hours prior to surgery with free access to water. Sedation with a mixture of midazolam/medetomidine/butorphanol was followed by endotracheal intubation and mechanical ventilation. Anesthesia was maintained with inhalational isoflurane. Midazolam and medetomidine were added according to the depth of anesthesia. Buprenorphine was administered as an intraoperative analgesic management. After intravenous administration of pentobarbital, saturated potassium chloride was rapidly administered intravenously to euthanize. Three animals were used to examine the flushing effect of the hydrogen-containing organ preservation solution and 9 animals were used for the organ transplantation experiment (one donor and two recipients were used for one set of experiments; n = 3). These experiments were conducted with the approval of the Research Council and Animal Care and Use Committee of Keio University \[approval no: 16072-(1)\]. Surgery was performed by a surgeon with over 200 clinical transplant operations, who is a steering member of the transplantation society and a permanent director of the transplantation society of Japan (E.K.).

Hydrogen gas dissolution system based on a hydrogen-absorbing alloy canister {#sec004}
----------------------------------------------------------------------------

The hydrogen-absorbing alloy canister (Japan Steel Works, Ltd.) was a cylinder containing a hydrogen-absorbing alloy that can reversibly absorb and release hydrogen ([Fig 1A](#pone.0222863.g001){ref-type="fig"}). Since the internal pressure of the canister does not exceed 1 MPa, it does not correspond to high-pressure gas according to the Japan High-Pressure Gas Safety Act. The device for transferring hydrogen was assembled just before use and hydrogen was infused into the organ preservation solution from the hydrogen-absorbing alloy canister via a pressure regulating valve ([Fig 1B and 1C](#pone.0222863.g001){ref-type="fig"}). When the gauge pressure reached 0.06 Mpa, the plastic bag containing the organ preservation solution was disconnected from the pressure regulating valve. After vigorous manual shaking for 30 seconds or more, the bag containing the organ preservation solution was placed on ice and opened to the atmosphere. Then the concentration of hydrogen gas in the solution was measured over time by gas chromatography (TRIlyzer mBA-3000; Taiyo Co., Ltd., Kochi, Japan).

![Novel method of dissolving hydrogen gas in organ preservation solution by using a hydrogen-absorbing alloy canister.\
(A) Mechanism of the hydrogen absorbing alloy. (B) Process of dissolving hydrogen in the organ preservation solution by using the hydrogen-absorbing alloy canister. (1) A hydrogen-absorbing alloy canister and a pressure regulating valve are connected to a bag of organ preservation solution. (2) Hydrogen gas is injected through the rubber stopper using a bottle needle. When the pressure reaches 0.06 Mpa, the bag of organ preservation solution is disconnected from the pressure regulating valve and hydrogen-absorbing alloy canister. (3) The organ preservation solution in the plastic bag is shaken vigorously by hand for more than 30 seconds. (4) The bag is opened to the atmosphere. (C) Components of the device for infusing hydrogen gas into organ preservation solutions.](pone.0222863.g001){#pone.0222863.g001}

Investigation of the effectiveness of hydrogen-containing preservation solution for flushing kidneys from donor pigs with circulatory arrest {#sec005}
--------------------------------------------------------------------------------------------------------------------------------------------

A midline upper abdominal incision was made under general anesthesia, and the left and right kidneys were dissected. Then the chest was opened and the thoracic aorta was clamped to induce ischemia of all abdominal organs. After 30 minutes of warm ischemia, the kidneys were removed for use as donor organs. The donor animal was not treated with an anticoagulant such as heparin. The excised kidneys were immediately placed on the back table, divided into the right and left kidneys, and perfused for 5 minutes by gravity feed from a height of 1 m. One kidney was perfused with hydrogen-containing cold extracellular-type trehalose-containing Kyoto (ETK) solution and the other was perfused with hydrogen-free cold ETK solution. The number of drops of the solution per minute was counted for each kidney.

Evaluation in a kidney transplantation model {#sec006}
--------------------------------------------

After flushing with either hydrogen-containing cold ETK solution or hydrogen-free cold ETK solution for 5 minutes, the harvested kidneys were immersed and stored in the same ETK solution for 1 to 4 hours until transplantation into the recipient.

Under general anesthesia, a midline abdominal incision was made to expose the recipient's left renal artery and vein \[[@pone.0222863.ref024]\]. After intravenous administration of 1 ml of heparin, the abdominal aorta was clamped immediately above the renal artery bifurcation. Then the renal vein was clamped with bulldog forceps, and the left kidney was resected from the renal artery leaving a Carrel patch configuration. Next, the stored donor kidney was anastomosed end-to-end with 5--0 nylon to the renal artery at the Carrel patch site. After arterial anastomosis, the peripheral renal artery was clipped again before unclamping the abdominal aorta. The total aortic clamp time was 30 minutes. Subsequently, the renal veins were joined by end-to-end continuous anastomosis with 6--0 nylon, and finally the ureter was anastomosed with 6--0 nylon knotted sutures. The transplanted kidney was wrapped in a thermal bag, and the temperature was kept at 20 °C or less by appropriate infusion of cold ETK solution \[[@pone.0222863.ref025]\]. Warm ischemic time was set at 1 hour. After reperfusion, blood flow was confirmed in the transplanted kidney. Then the right native kidney was excised and the abdomen was closed. Cefazolin sodium (25mg/kg) was given on the first postoperative day, and the animals were allowed free access to both food and water. The animals were observed for up to 6 days after surgery, and then were sacrificed for laboratory tests, urinalysis, and histopathological examination of the transplanted kidneys. Blood urea nitrogen (BUN) and creatinine (CRE) were measured in peripheral blood and urine samples by the urease-GLDH method and enzymatic method, respectively. Total urinary protein was measured by the pyrogallol red technique and urinary electrolytes were measured by an ion-selective electrode method, while inorganic phosphate (IP) was determined by an enzymatic method and glucose by the hexokinase/glucose-6-phosphate dehydrogenase method. The transplanted kidneys were fixed in 10% neutral buffered formaldehyde solution and cut in the longitudinal direction to include the papilla centering on the cortex. After embedding by a conventional method, thin sections were prepared and were stained with hematoxylin and eosin (H. E.) and Elastica van Gieson (EVG) stain. Histological examination was done by blinded pathologists and renal graft pathology was assessed according to the Banff classification \[[@pone.0222863.ref026], [@pone.0222863.ref027]\].

Results {#sec007}
=======

Hydrogen concentration profile in organ preservation solutions {#sec008}
--------------------------------------------------------------

The time required for infusion of hydrogen gas was 2--3 minutes. Changes of the hydrogen concentration in three organ preservation solutions after infusion of hydrogen gas are shown in [Fig 2](#pone.0222863.g002){ref-type="fig"}. At the same pressure, UW solution and HTK solution had higher hydrogen concentrations than ETK solution. The hydrogen concentration declined very slowly at 4 °C under normal pressure and was 1 mg/L or more after 4 hours in all of the solutions. As ETK solution does not require strict temperature control for kidney preservation \[[@pone.0222863.ref028], [@pone.0222863.ref029]\], subsequent experiments on flushing and preservation of donor kidneys were performed using this solution.

![Changes of the hydrogen concentration in organ preservation solutions (UW, HTK, and ETK) at atmospheric pressure after infusion of hydrogen gas.](pone.0222863.g002){#pone.0222863.g002}

Flushing effect of hydrogen-containing organ preservation solution {#sec009}
------------------------------------------------------------------

Transplantation of marginal donor organs was performed to assess the effectiveness of cold hydrogen-containing ETK solution generated by our hydrogen gas infusion method. We used miniature pigs (25--40 months old) to more closely reflect the clinical transplantation setting. After warm ischemic injury was created by circulatory arrest for 30 minutes, the donor kidneys were harvested and perfused for 5 minutes with hydrogen-containing cold ETK solution or hydrogen-free cold ETK solution ([Fig 3A](#pone.0222863.g003){ref-type="fig"}). When hydrogen-containing cold ETK solution was used, the perfusion rate was faster from the initial stage of perfusion than with hydrogen-free ETK solution ([Table 1](#pone.0222863.t001){ref-type="table"}). At the end of perfusion, visual inspection indicated that perfusion with hydrogen-containing ETK solution was more effective than use of hydrogen-free ETK solution ([Fig 3B](#pone.0222863.g003){ref-type="fig"}).

![Effectiveness of kidney flushing with hydrogen-containing ETK solution.\
A. The kidneys were perfused for 5 minutes by gravity feed (1 m). One kidney each was perfused with hydrogen-containing ETK solution and hydrogen-free ETK solution. B. 1) Kidney perfused with hydrogen-containing ETK solution; 2) Kidney perfused with hydrogen-free ETK solution.](pone.0222863.g003){#pone.0222863.g003}

10.1371/journal.pone.0222863.t001

###### ETK solution perfusion rate by gravity feed (1 m).

![](pone.0222863.t001){#pone.0222863.t001g}

                                     Experiment 1   Experiment 2                                          
  ---------------------------------- -------------- -------------- ---- ---- ---- ----- ----- ----- ----- -----
  Hydrogen-containing ETK solution   71             71             81   88   89   137   139   146   150   168
  Hydrogen-free ETK solution         60             63             68   68   73   78    78    83    85    88

The perfusion rate is shown as drops per minute.

Early post-transplant assessment of kidneys preserved with or without hydrogen-containing ETK solution {#sec010}
------------------------------------------------------------------------------------------------------

All of the recipient miniature pigs survived until the end of the observation period. After kidney storage for 1 hour before transplantation in hydrogen gas-free preservation solution, no urine was observed in the bladder and no blood flow was detected in the transplanted kidney at sacrifice on postoperative day 6 ([Table 2](#pone.0222863.t002){ref-type="table"}). On the other hand, after kidney storage in hydrogen gas-containing preservation solution for either 1 hour or 4 hours, blood flow was detected in the transplanted kidney and urine was found in the bladder on postoperative day 6. After transplantation of kidneys stored for 1 hour in hydrogen gas-free ETK solution, the blood levels of BUN and creatinine in the recipients were 270 ± 29.5 mg/dL and 4.72 ± 2.72 mg/dL, respectively (n = 3). After transplantation of a single kidney stored for 1 hour in hydrogen-containing ETK solution, blood levels of BUN and creatinine were 83 mg/dL and 4.4 mg/dL (n = 1), respectively. Therefore, the kidney storage time before transplantation was extended to 4 hours for the remaining two pigs in the hydrogen-containing ETK solution group. Despite longer storage, blood levels of BUN and creatinine were low at the time of sacrifice in 1 of these 2 animals, being 108 mg/dL and 8.2 mg/dL, respectively.

10.1371/journal.pone.0222863.t002

###### Laboratory data on day 6 after kidney transplantation.

![](pone.0222863.t002){#pone.0222863.t002g}

                                                  Blood   Urine                                                       
  ---------------------------------- ------ ----- ------- -------- ------- ------- ------- ------ ------ ------ ----- ---
  Hydrogen-free ETK solution         No.1   1     261     22.8     N.T                                                
  No.2                               1      224   20.0    N.T                                                         
  No.3                               1      325   29.2    N.T                                                         
  Hydrogen-containing ETK solution   No.1   1     83      4.4      327.6   405.5   99.07   15     35.5   12     0.8   8
  No.2                               4      108   8.2     41.0     682.5   81.28   23      30.6   13     44.2   1     
  No.3                               4      239   33.6    2491.0   290.1   51.11   89      39.9   75     17.9   61    

N.T; Not tested (no urine in the bladder)

Histopathological findings are displayed in [Fig 4](#pone.0222863.g004){ref-type="fig"}. In the hydrogen-free ETK solution group, all three kidneys showed extensive cortical necrosis (pan-necrosis). In the hydrogen gas-containing ETK solution group, there was evidence of acute tissue injury, but not cortical necrosis. Tubular dilation and cellular infiltration were noted at a low magnification, while infiltration of mononuclear cells and capillary occlusion were observed in the glomeruli at a high magnification. Infiltration of mononuclear cells and lymphocytes was also observed in the tubulointerstitial region. The pathological findings of transplanted kidneys preserved by using hydrogen-containing ETK solution are summarized in [Table 3](#pone.0222863.t003){ref-type="table"}.

![Histological findings of the kidneys on day 6 after transplantation.\
Specimen numbers correspond to those in [Table 2](#pone.0222863.t002){ref-type="table"}. A, C, E, G: low magnification (40x), B, D, F, H: high magnification (400x). (A, B) A kidney preserved by using hydrogen-free ETK solution shows extensive necrosis in most of the microscopic field, indicating pan-necrosis of the cortex. (C-H) No cortical necrosis was observed in kidneys preserved by using hydrogen gas-containing ETK solution. However, tubular dilation and interstitial mononuclear cell infiltration are evident.](pone.0222863.g004){#pone.0222863.g004}

10.1371/journal.pone.0222863.t003

###### Detailed histopathological findings of transplanted kidneys preserved with hydrogen-containing ETK solution.

![](pone.0222863.t003){#pone.0222863.t003g}

  Findings/ specimen no.                                        1       2                                          3
  ------------------------------------------------------------- ------- ------------------------------------------ -------
  **Cortical necrosis**                                         0       0                                          0
   Cell debris                                                  0       0                                          0
  **Acute rejection**                                           **2**   **1**                                      **3**
   Glomerulitis                                                 3       1                                          2
   Glomerular thrombus                                          0       0                                          1
   Thrombus                                                     0       0                                          2
   Interstitial mononuclear cell infiltration                   3       2                                          3
   Tubulitis                                                    3       2                                          3
   Intimal arteritis                                            2       0                                          3
   Intimal arteritis in medulla                                 0       3[^F)^](#t003fn002){ref-type="table-fn"}   0
  **Chronic allograft nephropathy**                             **1**   **1**                                      **1**
   Chronic transplant glomerulopathy, mesangial proliferation   2       1                                          2
   Interstitial fibrosis                                        1       1                                          1
   Tubular atrophy and loss                                     1       2                                          3
   Tubular degeneration and necrosis                            0       1                                          2
   Tubular dilatation                                           2       2                                          3
   Tubular regeneration                                         0       1                                          1
  Fibrous intimal thickening with elastica fragmentation        0       2                                          3
  Other                                                                                                            
  Hyaline casts                                                 1       2                                          3
  Cellular casts                                                1       1                                          2
  Neutrophil/ eosinophil infiltration                           1       1                                          1
  Hemorrhage                                                    1       1                                          1
  Congestion, outer medulla                                     2       1                                          1

Grading system: 0; No change, 1: Mild, 2: Moderate, 3; Severe.

^F)^ Fibrinoid change: nonspecific changes in arteries or veins

Discussion {#sec011}
==========

In this study, we developed a method of producing hydrogen-containing organ preservation solution by rapidly infusing hydrogen gas into organ preservation solution from a canister containing hydrogen-absorbing alloy. Since the source of hydrogen gas is a hydrogen-absorbing alloy canister, it can be easily and safely brought to the site of donor organ extraction, and hydrogen gas can be quickly infused into the organ preservation solution even in an emergency. Then the hydrogen-containing organ preservation solution can be used to flush the donor organ and preserve it during transport. When hydrogen gas was infused into a bag containing cold ETK organ preservation solution at a pressure of 0.06 MPa and the bag was subsequently opened to the air, we confirmed that the dissolved hydrogen concentration remained at 1.0 mg/L or higher for 4 hours.

While it has been shown that hydrogen gas is effective for preventing ischemia reperfusion injury \[[@pone.0222863.ref001]--[@pone.0222863.ref004]\], hydrogen gas is flammable at high concentrations and clinical use is limited by safety considerations. Our previous investigator-initiated clinical trial demonstrated that inhalation of hydrogen gas combined with coronary intervention could inhibit left ventricular remodeling after myocardial infarction \[[@pone.0222863.ref030]\]. In that trial, the subjects inhaled a gas mixture of hydrogen (1.3%), oxygen, and nitrogen. However, it is considered difficult to use a cylinder of pure hydrogen gas to dissolve hydrogen in an organ preservation solution at the site of organ donation.

Previous methods for dissolving hydrogen in organ preservation solutions have involved generation of hydrogen by electrolysis \[[@pone.0222863.ref018], [@pone.0222863.ref020], [@pone.0222863.ref021], [@pone.0222863.ref022]\] or by use of a hydrogen-generating agent \[[@pone.0222863.ref017]\], after which the hydrogen gas undergoes passive diffusion into the organ preservation solution. However, these methods are complicated and are unsuitable for clinical use since it requires 24--48 hours for the hydrogen gas concentration in the solution to reach 1 mg/L.

When hydrogen-containing ETK solution was compared with hydrogen-free ETK solution for perfusion of donor kidneys, the former showed a higher flow rate from the start of perfusion. Examination of the perfused tissue revealed dilation of capillaries and washout of microthromboses.

In this study, we performed short-term observation (up to the 6th postoperative day) after transplantation of kidneys with warm ischemic injury from donor miniature pigs with circulatory arrest. When transplantation was done after storage of the kidney in hydrogen gas-free organ preservation solution for 1 hour, the outcome was always primary non-function. In contrast, when transplantation was performed after storage in hydrogen-containing solution for up to 4 hours, blood flow was detected in the transplanted kidney and production of urine was observed. These results suggest that our method could potentially be used clinically for restoring damaged organs to transplantable organs.

Some limitations of our study should be considered. We focused on the acute postoperative period, so it is also necessary to examine long-term renal function in recipients on immunosuppressant therapy in the future. In addition, kidneys treated with the hydrogen gas-containing organ preservation solution still developed severe acute tubulointerstitial injury. However, it is possible that the combination of hydrogen-containing organ preservation solution with an intraoperative rinse \[[@pone.0222863.ref031]\], intraoperative or postoperative immunosuppressant therapy, or adjuvant cell therapy using cells such as mesenchymal stromal cells \[[@pone.0222863.ref032], [@pone.0222863.ref033]\] could allow kidneys from marginal donors that have not been usable to be transplanted in the future.

Conclusion {#sec012}
==========

In conclusion, we developed a device that can be used to rapidly infuse hydrogen gas into organ preservation solution at the site of donor organ removal. It is possible that flushing and preservation of organs with hydrogen gas-containing solution could increase the feasibility of performing transplantation from marginal donors.
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======================
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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29 Aug 2019

Thank you for the constructive suggestions for improving our original manuscript. According to the suggestions, we have revised the manuscript. Below please find our reply to each comment you kindly made in a point-by-point manner (your points in italics and our responses in plain type).

Point-by-point reply to Ms. Vicky Stabler

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Reply: We confirmed that our manuscript meets PLOS ONE\'s style requirements.

2\. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, (3) efforts to alleviate suffering, (4) number of animals, (5) source of animals.

Reply: Information on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, (3) efforts to alleviate suffering, (4) number of animals, (5) source of animals, were added to a "Miniature pigs" paragraph in the Material and Methods section as described below.

We used female pigs aged 25-40 months and weighing 20-26 Kg, purchased from Fujimicra Ltd., Shizuoka, Japan. Animals were treated in accordance with the Animal (Scientific Procedures) Protection Act 1986 of the United Kingdom. The pigs were housed in cages under temperature and light-controlled conditions (12-hour light/dark cycle) and were provided with food and water ad libitum. The pigs were fasted for 12 hours prior to surgery with free access to water. Sedation with a mixture of midazolam/medetomidine/butorphanol was followed by endotracheal intubation and mechanical ventilation. Anesthesia was maintained with inhalational isoflurane. Midazolam and medetomidine were added according to the depth of anesthesia. Buprenorphine was administered as an intraoperative analgesic management. After intravenous administration of pentobarbital, saturated potassium chloride was rapidly administered intravenously to euthanize. Three animals were used to examine the flushing effect of the hydrogen-containing organ preservation solution and nine animals were used for the organ transplantation experiment (one donor and two recipients were used for one set of experiments; n = 3). These experiments were conducted with the approval of the Research Council and Animal Care and Use Committee of Keio University \[approval no: 16072-(1)\]. Surgery was performed by a surgeon with over 200 clinical transplant operations, who is a steering member of the transplantation society and a permanent director of the transplantation society of Japan (E.K.).

3\. As part of your revision, please complete and submit a copy of the ARRIVE Guidelines checklist, a document that aims to improve experimental reporting and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility: <https://www.nc3rs.org.uk/arrive-guidelines>. Please include your completed checklist as a Supporting Information file. Note that if your paper is accepted for publication, this checklist will be published as part of your article.

Reply: We uploaded a copy of the ARRIVE Guidelines checklist as a Supporting Information file.

4\. Thank you for stating the following in the Financial Disclosure section: This work was supported by grants from Doctors Man Co., Ltd. Doctors Man Co., Ltd had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We note that you received funding from a commercial source: Doctors Man Co., Ltd. Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc. Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Reply: We amended Competing Interests Statement and included our amended Competing Interests Statement within our cover letter.

 

Point-by-point reply to the editors and reviewers

Editors

We noted that certain details of animal experimental procedures are missing from the methods, specifically a description of the method of \[sacrifice/euthanasia, anaesthesia, etc.\].

Reply: Information on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, (3) efforts to alleviate suffering, (4) number of animals, (5) source of animals, were added to a "Miniature pigs" paragraph in the Material and Methods section.

We used female pigs aged 25-40 months and weighing 20-26 Kg, purchased from Fujimicra Ltd., Shizuoka, Japan. Animals were treated in accordance with the Animal (Scientific Procedures) Protection Act 1986 of the United Kingdom. The pigs were housed in cages under temperature and light-controlled conditions (12-hour light/dark cycle) and were provided with food and water ad libitum. The pigs were fasted for 12 hours prior to surgery with free access to water. Sedation with a mixture of midazolam/medetomidine/butorphanol was followed by endotracheal intubation and mechanical ventilation. Anesthesia was maintained with inhalational isoflurane. Midazolam and medetomidine were added according to the depth of anesthesia. Buprenorphine was administered as an intraoperative analgesic management. After intravenous administration of pentobarbital, saturated potassium chloride was rapidly administered intravenously to euthanize. Three pigs were used to examine the flushing effect of the hydrogen-containing organ preservation solution and nine pigs were used for the organ transplantation experiment (one donor and two recipients were used for one set of experiments; n = 3). These experiments were conducted with the approval of the Research Council and Animal Care and Use Committee of Keio University \[approval no: 16072-(1)\]. Surgery was performed by a surgeon with over 200 clinical transplant operations, who is a steering member of the transplantation society and a permanent director of the transplantation society of Japan (E.K.).

Animal experimental procedures for donor surgery and recipient surgery are detailed in "Investigation of the effectiveness of hydrogen-containing preservation solution for flushing kidneys from donor pigs with circulatory arrest" and "Evaluation in a kidney transplantation model" paragraph in Materials and Methods session.

Below, we described separately for Donor surgery and Recipient surgery.

Donor surgery

A midline upper abdominal incision was made under general anesthesia, and the left and right kidneys were dissected. Then the chest was opened and the thoracic aorta was clamped to induce ischemia of all abdominal organs. After 30 minutes of warm ischemia, the kidneys were removed for use as donor organs. The donor animal was not treated with an anticoagulant such as heparin. The excised kidneys were immediately placed on the back table, divided into the right and left kidneys, and perfused for 5 minutes by gravity feed from a height of 1 m. One kidney was perfused with hydrogen-containing cold extracellular-type trehalose-containing Kyoto (ETK) solution and the other was perfused with hydrogen-free cold ETK solution. The number of drops of the solution per minute was counted for each kidney.

Recipient surgery

Under general anesthesia, a midline abdominal incision was made to expose the recipient's left renal artery and vein (24). After intravenous administration of 1 ml of heparin, the abdominal aorta was clamped immediately above the renal artery bifurcation. Then the renal vein was clamped with bulldog forceps, and the left kidney was resected from the renal artery leaving a Carrel patch configuration. Next, the stored donor kidney was anastomosed end-to-end with 5-0 nylon to the renal artery at the Carrel patch site. After arterial anastomosis, the peripheral renal artery was clipped again before unclamping the abdominal aorta. The total aortic clamp time was 30 minutes. Subsequently, the renal veins were joined by end-to-end continuous anastomosis with 6-0 nylon, and finally the ureter was anastomosed with 6-0 nylon knotted sutures. The transplanted kidney was wrapped in a thermal bag, and the temperature was kept at 20 °C or less by appropriate infusion of cold ETK solution (25). Warm ischemic time was set at 1 hour. After reperfusion, blood flow was confirmed in the transplanted kidney. Then the right native kidney was excised and the abdomen was closed. Cefazolin sodium (25mg/kg) was given on the first postoperative day, and the animals were allowed free access to both food and water. The animals were observed for up to 6 days after surgery, and then were sacrificed for laboratory tests, urinalysis, and histopathological examination of the transplanted kidneys.

 

Reviewer \#1

1\. As shown in this paper, new methods seem easy and useful to prepare before organ transplant, especially for emergency. However, there was no discussion about cost effectiveness of this method compared to conventional methods. Please discuss about this in the discussion section.

Response:

Thank you very much for kind remarks and thoughtful comments. For drinking water, a hydrogen-absorbing alloy canister is sold at a rental fee of ¥ 30,000 per month. This technology has been patented and we want to make it extremely cheap to effectively spread. The superiority compared to other devices is described in the discussion.

2\. As authors commented in limitation, this paper did not show long-term prognosis of transplanted organ. However, many papers showed long-term effect of hydrogen gas containing solution for transplanted organs. Authors should show long-term prognosis of transplanted organ. Readers of this journal want to know about this.

Response

The use of immunosuppressants is necessary to achieve long-term results. The paper was done without the use of immunosuppressive agents to see the direct effects of hydrogen gas alone. In the future, a long-term effect of hydrogen gas containing solution for transplanted organs using immunosuppressive drugs is also planned.

3\. As shown in Organ Biology 2014; 21: 150-158 and Organ Biology 2015; 22: 117-120, the effect of hydrogen gas for transplanted organ is related to anti-inflammatory function, such as inducing heme oxygenase-1 and/or activating NF-E2-related factor 2. Authors should show the molecular mechanism of hydrogen-gas containing solution for transplanted kidney in this method.

Response

Because it is a very marginal graft in a large animal model, a biopsy immediately after reperfusion was avoided. In this paper, we have shown clinical utility, not a mechanism.

4\. There was no data about the biological significance of hydrogen gas containing ETK solution compared to UW and HTK. As authors declare UW and HTK solution had high hydrogen concentration at the beginning, authors should show the biologically significant data about ETK.

Response

In the previous experiment on transplantation of organs removed from rats after cardiac arrest, we observed that edema was reduced by using extracellular-type trehalose containing Kyoto solution (ETK) as a flash-out solution. As a result, ETK was used. References were as follows.

1\. Iwai S, Kikuchi T, Kasahara N, Teratani T, Yokoo T, Sakonju I, et al. Impact of normothermic preservation with extracellular type solution containing trehalose on rat kidney grafting from a cardiac death donor. PLoS One 2012; 7: e33157 (Ref 28)

2\. Kaimori JY, Iwai S, Hatanaka M, Teratani T, Obi Y, Tsuda H, Isaka Y, Yokawa T, Kuroda K, Ichimaru N, Okumi M, Yazawa K, Rakugi H, Nonomura N, Takahara S, Kobayashi E. Non-invasive magnetic resonance imaging in rats for prediction of the fate of grafted kidneys from cardiac death donors. PLoS One. 2013 May 7;8(5):e63573 (Added as Ref 33)

5\. As authors commented in limitation, it is well known that hydrogen-gas containing solutions still develop severe tubulointerstitial injury. However, in this study, transplanted kidney immediately worked well after transplanted. Is there any biological advantage in this new method? Authors should show the effectiveness compared to other hydrogen-gas containing methods.

Response

Thank you very much for kind remarks. The biological advantage of hydrogen-gas containing organ preservation solution for transplanted organs has been proven in many studies so far (Ref 6-22). In this study, we showed that hydrogen-gas containing organ preservation solution can revive damaged organs removed from an elderly miniature pig whose blood flow has stopped for 30 minutes to a transplantable organ to some extent. Various methods have been devised to dissolve hydrogen gas in organ preservation solutions, including use of a hydrogen gas cylinder, electrolysis, or a hydrogen-generating agent. However, these methods require considerable time and effort for preparation. We first made a practical hydrogen gas supply device at the site where organs are removed from donors. The canister storing hydrogen can be safely transported anywhere and can be easily connected to a bag containing conventional organ preservation solution, allowing hydrogen to be dissolved in organ preservation solution within a few minutes at the site of donor organ harvesting. These advantages are described in the discussion.

Reviewer \#2:

They developed a method of producing hydrogen-containing organ preservation solution by rapidly infusing hydrogen gas into organ preservation solution from a canister containing hydrogen-absorbing alloy. The results are interesting. If they can perform additional histology of azan staining or tunel staining, it would be more convincing.

Response

Thank you very much for a kind remark and a suggestion. The kidney sessions were assessed based on Banff classification of Renal Allograft Pathology, an international consensus on renal transplant biopsy reporting (Table 3).

According to reviewer's suggestion, TUNEL staining was performed, and the number of TUNEL positive cells in tubular epithelial cells was counted. There was a tendency for the number of TUNEL positive cells to be less with hydrogen-containing solution compared with hydrogen-free solution under the condition of 1 hour storage time, but the difference was not significant. At 6 days after transplantation, with hydrogen-containing solution, the increase in BUN/CRTNIN was suppressed, urine excretion was observed, and histologically, transplanted kidney did not fall into cortical necrosis. By contrast, sub-optimal (marginal) kidney did not tolerate conventional cold storage and showed cortical necrosis and never function (primary non-functioning).

These results suggest that hydrogen may suppress cell death by mechanisms other than apoptosis.　Or as a more likely possibility, hydrogen gas could restore the microvasculature and improve the blood circulation, thereby accelerating the functional recovery of the transplanted kidney, rather than suppressing apoptotic cell death based on ischemia-reperfusion injury. This is consistent with the result that hydrogen-containing solution promotes the effect of washing out blood from organs extracted from marginal donors. Examination of the perfused tissue revealed dilation of capillaries and washout of micro-thromboses. Since this content is related to the patent currently being prepared for application, we will refrain from making a description in this paper.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Organ preservation solution containing dissolved hydrogen gas from a hydrogen-absorbing alloy canister improves function of transplanted ischemic kidneys in miniature pigs

PONE-D-19-15185R1

Dear Dr. Sano,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Tohru Minamino, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript is adequately corrected. However, English editing is required by native English speaker before publication.

Reviewer \#2: The authors performed additonal experiments and answered well to my concerns. This paper is now acceptable.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#2: No
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Organ preservation solution containing dissolved hydrogen gas from a hydrogen-absorbing alloy canister improves function of transplanted ischemic kidneys in miniature pigs

Dear Dr. Sano:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff
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Professor Tohru Minamino
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